P526 A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trial
R Van Linschoten(Erasmus MC), Frank Hoentjen(Radboud University Nijmegen), Adriaan C.I.T.L. Tan(Canisius-Wilhelmina Ziekenhuis), Rosalie C. Mallant–Hent, Alexander Bodelier(Amphia Ziekenhuis), Frank H.J. Wolfhagen(Albert Schweitzer Ziekenhuis), Robert West(The Behaviouralist (United Kingdom)), N de Boer(University of Amsterdam), A Van Bodegraven(Zuyderland Medisch Centrum), Maurice Lutgens(Elisabeth-TweeSteden Ziekenhuis), Fenna M. Jansen(Radboud University Nijmegen), J Jansen, R Pauwels(Erasmus MC), F Atsma(Radboud University Nijmegen), W Kievit(Radboud University Nijmegen), Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Pieter ter Borg(Ikazia Ziekenhuis), C. Janneke van der Woude(Radboud University Nijmegen), Paul J. Boekema(Radboud University Nijmegen), Lisa Smits(Radboud University Nijmegen), Ingrid Gisbertz(Ziekenhuis Bernhoven), Debora de Jong(University of Groningen), Annemarie de Vries(Erasmus University Rotterdam), Sanne Jansen(Reinier de Graaf Hospital), M. Russel(Medisch Spectrum Twente), A van der Meulen-de Jong(Leiden University Medical Center), Bas Oldenburg(University Medical Center Utrecht)
Cited by 0
Related Papers
Cassini Observes the Active South Pole of Enceladus
|Science|2006|1.2k
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
|Gastroenterology|2015|478